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High Soluble CD30, CD25, and IL-6 May Identify
Patients with Worse Survival in CD30þ Cutaneous
Lymphomas and Early Mycosis Fungoides
Marshall E. Kadin1, Igor Y. Pavlov2, Julio C. Delgado2 and Eric C. Vonderheid3,4
Histopathology alone cannot predict the outcome of patients with CD30þ primary cutaneous lymphoprolif-
erative disorders (CD30CLPD) and early mycosis fungoides (MF). To test the hypothesis that serum cytokines/
cytokine receptors provide prognostic information in these disorders, we measured soluble CD30 (sCD30),
sCD25, and selected cytokines in cell cultures and sera of 116 patients with CD30CLPD and 96 patients with early
MF followed up to 20 years. Significant positive correlation was found between sCD30 levels and sCD25, CD40L,
IL-6, and IL-8, suggesting that CD30þ neoplastic cells secrete these cytokines, but not Th2 cytokines. In vitro
studies confirmed that sCD30, sCD25, IL-6, and IL-8 are secreted by CD30CLPD-derived cell lines. CD30CLPD
patients with above normal sCD30 and sCD25 levels had worse overall and disease-related survivals, but only
sCD30 retained significance in Cox models that included advanced age. High sCD30 also identified patients
with worse survival in early MF. Increased IL-6 and IL-8 levels correlated with poor disease-related survival in
CD30CLPD patients. We conclude that (1) neoplastic cells of some CD30CLPD patients do not resemble Th2
cells, and that (2) high serum sCD30, sCD25, IL-6, and perhaps IL-8 levels may provide prognostic information
useful for patient management.
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INTRODUCTION
Some investigators have suggested that current clinical and
histological criteria are inadequate to predict outcome in
CD30þ primary cutaneous lymphoproliferative disorders
(CD30CLPD) (Bekkenk et al., 2000). Most patients with
CD30CLPD have an excellent prognosis, but up to 20%
progress to systemic involvement or develop a second
lymphoma such as mycosis fungoides (MF) or Hodgkin’s
lymphoma (HL; Bekkenk et al., 2000; Gruber et al., 2006). At
presentation, the natural history of CD30CLPD is often not
apparent and may be modified by subsequent molecular/
genetic events (Kadin, 2006). Clinical monitoring is essential
for patient management. We hypothesize that measurement
of serum cytokines/cytokine receptors could improve the
ability to predict prognosis of CD30CLPD.
CD30/TNFRSF8 is a co-stimulatory molecule expressed on
activated T and B cells commonly used as a marker for
neoplastic cells of HL, systemic anaplastic large-cell lym-
phoma (sALCL), and CD30CLPD (Stein et al., 1985;
Borchmann, 2008). Serum levels of sCD30 correlate with
tumor burden and normalize following successful treatment
of HL (Nadali et al., 1994) and sALCL (Zinzani et al., 1998).
Similarly, serum levels of the soluble truncated a-chain of the
IL-2 receptor (sCD25) expressed by activated immune cells
correlate with disease activity and prognosis in HL (Gause
et al., 1992), sALCL (Gause et al., 1992), and MF (Gause
et al., 1992; Wasik et al., 1996). However, the clinical
significance of sCD25 levels has not been reported in
CD30CLPD. Herein, we report our retrospective analysis of
serum levels of sCD30, sCD25, and other cytokine/cytokine
receptors for patients with CD30CLPD and early MF.
RESULTS
sCD30
Our primary objective was to measure sCD30 levels in cases
of CD30CLPD and correlate results with clinical observations
including prognosis. Of 116 cases of CD30CLPD, sCD30 was
increased above normal reference laboratory values in 10
(9%) cases (Table 1). Within this group, 2 of 15 (13%) cases of
lymphomatoid papulosis (LyP) type C and 2 of 13 (15%) cases
of primary cutaneous anaplastic large-cell lymphoma
(pcALCL) had increased sCD30 levels compared with 6 of
87 (7%) LyP types A or B. Median sCD30 levels also tended
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to be higher in LyP-C and pcALCL cases compared with
LyP-A or -B cases. Although not statistically significant, this
observation suggests a relationship between the density of
CD30þ cells in evaluated skin lesions and sCD30 levels.
In the absence of banked sera from concurrent normal
controls, inflammatory skin disease (ISD) cases with absent to
rare CD30þ cells in the dermal infiltrate were compared
against other disease categories (Table 1). As expected, no
ISD case had sCD30 values that exceeded 29 ngml1, the
top normal reference value. Compared with CD30-low ISD,
significantly higher levels of sCD30 were observed for all
subtypes of CD30CLPD, as well as patients with early MF
and patients with CD30CLPD coexisting with early MF
(CD30CLPD/MF). A total of 16 of 19 (84%) patients with
various advanced CD30þ cutaneous lymphomas (CD30-
high controls) had above normal sCD30 levels, supporting
the correlation of increased sCD30 levels and disease
severity.
Correlation of sCD30 with Th2 cytokines
Considering that CD30 may be a marker of Th2-polarized
CD4þ cells (Del Prete et al., 1995), we correlated sCD30
with Th2 and other cytokines in CD30CLPD. Statistically
significant positive correlations were found between
sCD30 and sCD25 (Spearman’s correlation rho¼0.510,
Po0.001), sCD40L (rho¼0.411, Po0.001), IL-6 (rho¼ 0.252,
P¼0.007), and IL-8 (rho¼0.322, Po0.001), but not IL-4
(rho¼0.116, P¼ 0.214), the prototypic Th2 cytokine, nor IL-5
(rho¼0.164, P¼ 0.079) and IL-13 (rho¼ 0.130, P¼0.164).
These results suggest that CD30-secreting cells do not secrete
abundant Th2 cytokines other than IL-6 (and perhaps IL-10,
which was not studied because of technical problems), and by
inference non-neoplastic cells may be a source of Th2
cytokines in CD30CLPD.
CD30CLPD coexisting with MF
Compared with CD30-low ISD controls, the CD30CLPD/MF
group had significantly higher sCD30 levels (Po0.001), but
not sCD25 (Tables 1 and 2). Patients with CD30CLPD/MF
also had significantly lower levels of IFN-g (P¼0.029),
IL-12 (P¼0.034), IL-4 (P¼ 0.027), and possibly IL-2
(P¼0.057). Compared with CD30-low MF cases, no
significant differences in any biomarker were observed.
These findings suggest that the cytokine profile of patients
with CD30CLPD/MF is not skewed toward either Th1- or
Th2-polarized profile.
sCD25
Compared with ISD controls, sCD25 levels were significantly
higher for cases of CD30CLPD and CD30CLPD/MF, as well
as the CD30-high control group (Table 2). Although above
normal serum values (41,033 pgml1) occurred in only 8%
of the CD30CLPD cases, sCD25 was more often increased in
cases with numerous CD30þ cells in lesions, i.e., LyP-C
(13%) and pcALCL (23%) compared with LyP-A or B (5%;
Pearson’s exact w2, P¼0.036). Because sCD25 and sCD30
Table 1. Serum sCD30 levels in patients with CD30+ primary cutaneous lymphoproliferative disease and early
mycosis fungoides
Diagnosis (no. in cohort) No. with high sCD30 (%)1 Median (range) Mean±SD P-value2 P-value3
CD30CLPD (116) 10 (9) 10.1 (0.1–599.2) 20.8±59.6 o0.001 0.606
LyP (103) 8 (8) 10.0 (0.1–207.2) 15.9±26.0 o0.001 0.798
LyP-A or B (87) 6 (7) 9.5 (0.1–121.9) 14.1±18.8 0.001 0.917
LyP-C (16) 2 (13) 12.5 (0.6–207.2) 25.9±49.5 0.002 0.239
pcALCL (13) 2 (15) 13.0 (2.6–599.2) 59.3±162.6 0.002 0.243
CD30CLPD/MF4 (16) 1 (6) 14.3 (2.1–70.0) 16.4±15.6 o0.001 0.084
CD30-high controls5 (19) 16 (84) 109.7 (10.9–2,798.6) 377.9±650.8 o0.001 o0.001
CD30-low controls6
Early MF7 (96) 6 (6) 9.5 (0.1–102.2) 12.3±13.2 o0.001
ISD8 (22) 0 (0) 5.2 (0–11.7) 5.2±3.7 o0.001
Abbreviations: CD30CLPD, CD30+ primary cutaneous lymphoproliferative disease; ISD, inflammatory skin disease; LyP, lymphomatoid papulosis;
MF, mycosis fungoides; pcALCL, primary cutaneous anaplastic large cell lymphoma.
1Normal laboratory range for sCD30, 1–29 ngml1.
2Compared against CD30-low ISD control group using Kruskal–Wallis test.
3Compared against CD30-low MF control group using Kruskal–Wallis test.
4Early MF coexisting with LyP (13 cases) or pcALCL (3 cases).
5Includes 15 cases of advanced CD30+ CTCL (13 large cell transformation), one case of CD30+ pleomorphic T cell lymphoma with mild erythroderma,
one case of extensive pagetoid reticulosis expressing CD30 and CD25, and one case of adult T cell lymphoma with CD30+ papules and plaques and lymph
node involvement.
6Absent or rare CD30+ cells in dermal infiltrate.
7Includes unilesional (14 cases), hypopigmented (3 cases), purpuric (3 cases), folliculotropic (2 cases), and palmoplantar (2 cases) variants.
8Includes digitate parapsoriasis en plaques (13 cases), pityriasis lichenoides (6 cases), and erythema annulare centrifugum (3 cases).
704 Journal of Investigative Dermatology (2012), Volume 132
ME Kadin et al.
Cytokines in CD30þ Cutaneous Lymphoma
levels correlated strongly (rho¼ 0.510), this suggests the
possibility of a common cellular source.
IL-6 and IL-8
IL-6 and IL-8 levels were significantly increased in cases of
CD30CLPD compared with ISD controls (Table 3; Supple-
mentary Table S1 online). IL-6 levels were above normal in
27% of CD30CLPD patients (about 40% of LyP-C and
pcALCL cases versus 25% of LyP-A or B cases). IL-8 was
above normal in only 10% of CD30CLPD cases, and
correlation with histopathological subsets was not apparent.
Effect of storage time on serum cytokine/cytokine receptor
levels
These studies were conducted on samples stored for 6 to 21
years (median, 11 years). If cytokine/cytokine receptor levels
Table 2. Serum sCD25 levels in patients with CD30+ primary cutaneous lymphoproliferative disease and early
mycosis fungoides
Diagnosis (no. in cohort) No. with high sCD25 (%)1 Median (range) Mean±SD P-value2 P-value3
CD30CLPD (116) 9 (8) 444 (44–7,285) 581±724 0.009 0.898
LyP (103) 6 (6) 427 (44–7,285) 562±746 0.015 0.783
LyP-A or B (87) 4 (5) 436 (44–7,285) 551±779 0.019 0.685
LyP-C (16) 2 (13) 421 (49–2,306) 617±545 0.051 0.784
pcALCL (13) 3 (23) 548 (108–1,801) 733±523 0.014 0.114
CD30CLPD/MF (16) 2 (13) 467 (25–1,212) 528±341 0.076 0.790
CD30-high controls (19) 14 (74) 1,468 (334–133,066) 9,325±30,198 o0.001 o0.001
CD30-low controls
Early MF (96) 7 (7) 449 (11–2,042) 523±372 0.015
ISD (22) 0 (0) 233 (10–947) 329±286 0.015
Abbreviations: CD30CLPD, CD30+ primary cutaneous lymphoproliferative disease; ISD, inflammatory skin disease; LyP, lymphomatoid papulosis;
MF, mycosis fungoides; pcALCL, primary cutaneous anaplastic large cell lymphoma.
1Normal laboratory reference for sCD25, 0–1,033 pgml1.
2Compared against CD30-low ISD control group using Kruskal–Wallis one-way analysis of variance.
3Compared against CD30-low MF control group using Kruskal–Wallis one-way analysis of variance.
Table 3. Serum IL-6 levels in patients with CD30+ primary cutaneous lymphoproliferative disease and early
mycosis fungoides
Diagnosis (no. in cohort) No. with high IL-6 (%)1 Median (range) Mean±SD P-value2 P-value3
CD30CLPD (116) 31 (27) 1.6 (0–238.8) 13.1±38.6 0.003 0.002
LyP (103) 26 (25) 1.5 (0–238.8) 13.8±40.8 0.004 0.003
LyP-A or B (87) 20 (23) 1.5 (0–238.8) 13.3±39.3 0.008 0.009
LyP-C (16) 6 (38) 2.0 (0–200.7) 16.7±49.4 0.005 0.015
pcALCL (13) 5 (38) 2.6 (0–36.9) 7.7±11.5 0.023 0.080
CD30CLPD/MF (16) 3 (19) 0.9 (0–26.4) 4.3±8.7 0.415 0.794
CD30-high controls (19) 8 (42) 4.1 (0.2–33.9) 9.8±10.6 o0.001 o0.001
CD30-low controls
Early MF (96) 14 (15) 0.9 (0–110.1) 4.5±14.1 0.273
ISD (22) 0 (0) 0.6 (0–4.3) 1.0±1.2 0.273
Abbreviations: CD30CLPD, CD30+ primary cutaneous lymphoproliferative disease; ISD, inflammatory skin disease; LyP, lymphomatoid papulosis;
MF, mycosis fungoides; pcALCL, primary cutaneous anaplastic large cell lymphoma.
1Normal laboratory reference for IL-6, 0–5 pgml1.
2Compared against CD30-low ISD control group using Kruskal–Wallis test.
3Compared against CD30-low MF control group using Kruskal–Wallis test.
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deteriorated over time, one might expect a negative correla-
tion with storage time. However, only transforming growth
factor-b had a significant negative correlation for the entire
data set (rho¼0.145, P¼ 0.015); the correlations for
sCD30, sCD25, and IL-6 were rho¼0.058, 0.035, and
0.044, respectively.
Effect of CD30 ligand on sCD30
To investigate whether sCD30 serum levels might be suppressed
by its ligand, we correlated sCD30 with sCD30L/CD153 in
77 samples covering a wide range of sCD30 values (range
0–2,798.6 ngml1). No significant correlation was found
between these cytokines (rho¼0.035, P¼ 0.760). This
observation suggests that sCD30 levels are not inhibited or
removed by high sCD30L/CD153 in the blood.
Repeat specimens on patients responding to treatment
Blood samples obtained at baseline and after a complete
response to treatment were available for 8 patients with
CD30CLPD (3 LyP-A, 2 LyP-C, 3 pcALCL) and 10 patients
with early MF (Table 4). Of the cytokines studied, only sCD25
levels of patients with CD30CLPD showed a significant
decrease post treatment (P¼ 0.023, Wilcoxon test). For these
eight patients, sCD30 levels did not correlate with treatment
response.
Cytokine levels in supernatants of CD30þ cell lines
As shown in Table 5, abundant levels of sCD30 and sCD25
were detected in supernatants of CD30CLPD-derived cell
lines Mac1 and Mac2A, and sALCL cell line JB6. Compared
with Mac 1 cells, Mac 2A cells secreted larger amounts of
IL-6 and IL-13. Mac 2A and JB6 cells also secreted small
amounts of IL-8, but neither cell line secreted prototypic Th2
cytokines (IL-4, IL-5, IL-10). JB6 sALCL cells secreted
abundant IL-10. These results indicate that CD30CLPD-
derived cells are capable of secreting various cytokines other
than Th2-type cytokines.
Prognostic implications
In this cohort, only 1 of 87 (1.2%) patients presenting with
LyP-A or -B, 2 of 16 (12.5%) patients with LyP-C, and 2 of 13
(15.4%) patients with pcALCL experienced documented
disease progression and related death (P¼0.033). No patient
developed HL. Details are provided in Supplementary Tables
S2 and S3 online. Because information about the specific
cause of death was not available for 20 patients, the actual
disease-related death rate may be higher than 5 of 116 (4.3%).
The relationship between clinical parameters, levels of
cytokines/receptors, and survival of patients with CD30CLPD
were analyzed using Cox and Kaplan–Meier models. With all
causes of death as the event, significant differences were
found for several clinicopathological parameters: patients’
age (continuous variable ando60 vs.460 years, Po0.001),
race (white vs. other, P¼ 0.018), and histopathological
subtype (P¼0.024). The difference in survival was significant
between pcALCL and LyP-A or -B, but not between pcALCL
and LyP-C (Supplementary Figure S1 online). For disease-
related deaths, significant differences in survival occurred
Table 4. Comparison of sCD30, sCD25, and IL-6 values in selected patients who achieved a CR from treatment
Cohort No. of pts Cytokine Baseline CR % Change mean±SD P-value1
CD30CLPD 8 sCD30 10.3±7.6 11.1±4.4 +51.0±121.1 0.742
8 sCD25 711±557 419±268 34.5±28.3 0.023
8 IL-6 5.8±7.5 3.6±4.2 +3.1±126.4 0.547
MF 10 sCD30 19.7±23.0 16.9±19.9 4.8±27.7 0.383
10 sCD25 1,255±1,877 1,257±2,350 +1.5±54.3 0.695
10 IL-6 7.6±11.4 3.2±3.2 45.9±48.4 0.148
Abbreviations: CD30CLPD, CD30+ primary cutaneous lymphoproliferative disease; CR, complete response; MF, mycosis fungoides; pts, patients.
1Change in cytokine median values tested using Wilcoxon test.
Table 5. Cytokine levels in CD30CLPD-derived cell cultures
Cell line sCD30 (ngml1) sCD25 (pgml1) IFN-c (pgml1) IL-4 (pgml1) IL-6 (pgml1) IL-8 (pgml1) IL-10 (pgml1) IL-13 (pgml1)
RPMI/FBS1 0 0 o10 0 0 0 0 0
Mac-1 2,757 410,240 25 0 1 4 20 2
Mac-2A 49,000 410,240 o10 0 7,395 17 0 3,067
JB-6 4,002 410,240 o10 0 0 56 410,240 0
Abbreviations: CD30CLPD, CD30+ primary cutaneous lymphoproliferative disease; FBS, fetal bovine serum; RPMI, Roswell Park Medium.
Cell cultures were seeded at 106 cells per ml and incubated for 48 hours in RPMI/FBS. Conditioned media was centrifuged to remove cells and supernatants
collected and frozen immediately at 20 1C.
1RPMI with 10% FBS.
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between both pcALCL and LyP-C versus LyP-A or -B, whereas
no difference was observed between pcALCL and LyP-C.
Although the frequency of CD30CLPD-related deaths was
only 4.3%, it is consistent with other studies (Bekkenk et al.,
2000). Furthermore, the LyP-C subset may have a greater
potential for disease progression than LyP-A or -B, although
an impact on overall survival was not demonstrated.
Similarly, univariate analysis identified several biomarkers
as being significantly associated with worse overall survival
when categorized into clinically useful normal versus above
normal results: increased sCD30, sCD25, and IL-8 levels, but
not IL-6 (nor lactate dehydrogenase in a limited model)
(Supplementary Table S4 online). Interestingly, an above
normal level of transforming growth factor-b correlated with
improved survival. When analyzed using disease-related
death as the event, increased sCD30, sCD25, IL-6, (and
lactate dehydrogenase), but not IL-8, levels were signifi-
cantly associated with adverse prognosis. Survival curves for
sCD30, sCD25, and IL-6 are shown in Figures 1 and 2 and
Supplementary Figure S2 online, respectively.
Multivariate analysis was then performed using the
following categorized variables: age (o60, 460 years), race
(white, other), histopathological subsets (LyP, pcALCL), as
well as sCD30, sCD25, IL-6, and IL-8 (normal, above normal)
levels. For all causes of death as the event, advanced age,
race other than white, and above normal sCD30 levels were
identified as independently significant prognostic indicators
(Supplementary Table S5 online). For a model in which age,
histopathological subset, and sCD30 were analyzed together,
only age and sCD30 were significant. Increased sCD30
significantly correlated with overall survival in most other
models, but increased IL-8 level also was independently
significant in some (data not shown).
A similar multivariate analysis using disease-related death
as the event identified age and above normal IL-6 levels
(hazard ratio, 9.206) to provide more prognostically im-
portant information than increased sCD30, sCD25, and IL-8
levels (or lactate dehydrogenase; Supplementary Figure S2
online). The reason appears to be that four of the five patients
with disease-related deaths had above normal IL-6 levels
compared with only two patients for sCD30 and sCD25 and
only one for IL-8 (Supplementary Table S2 online). Finally, no
difference in survival was found for patients with CD30CLPD/
MF compared with CD30CLPD.
The prognostic implication of sCD30 and other markers
was similarly investigated for the 96 patients with early MF.
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Figure 1. Survival of patients with CD30þ primary cutaneous
lymphoproliferative disease according to low normal, high normal, and
above normal sCD30 levels. (a) All causes of death; (b) disease-related death.
1.0
0.9
0.8
Su
rv
iva
l f
un
ct
io
n
0.7
0.6
0 50 100
sCD25 level pg ml–1
150
Months
P = 0.016
200 250
1.0
0.9
0.8
Su
rv
iva
l f
un
ct
io
n
0.7
0.6
0.5
0.4
0.3
0.2
0 50 100
sCD25 level pg ml–1
44 to < 400 (N=49)
400 to 1,033 (N=58)
> 1,033 (N=9)
44 to < 400 (N =49)
400 to 1,033 (N =58)
> 1,033 (N =9)
150
Months
P =0.004
200 250
a
b
Figure 2. Survival of patients with CD30þ primary cutaneous
lymphoproliferative disease according to low normal, high normal, and
above normal sCD25 levels. (a) All causes of death; (b) disease-related death.
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Univariate analysis identified patients’ age, sCD30 and
sCD25 levels to be correlated significantly with prognosis
(all causes of death). However, with age as a covariate, high
sCD30, but not sCD25, levels retained significance (Supple-
mentary Table S5 online, Supplementary Figure S3 online).
Although only four (4.2%) early MF patients died of disease,
high sCD30 levels remained independently significant
(hazard ratio, 11.644) with regard to disease-related survival.
DISCUSSION
We investigated the clinical significance of sCD30 and other
biomarkers in 116 patients with CD30CLPD and 96 patients
with early MF. Considering that CD30 and CD25 are
expressed by the atypical cells in skin lesions of LyP,
particularly histological subtypes A and C, and pcALCL
(Willemze and Beljaards, 1993; El Shabrawi-Caelen et al.,
2004; Willemze et al., 2005), it was not surprising that serum
levels of these markers in CD30CLPD patients were
significantly higher than that in CD30-low ISD cases. We
also found that increased sCD30 and sCD25 levels were
associated with worse overall and disease-related survivals,
suggesting that the levels might reflect the number of
neoplastic cells in the skin and identify patients with an
increased risk for disease progression. In a Cox model that
included advanced age (X60 years), increased sCD30 levels
were a better predictor of prognosis than either sCD25 or
histopathological classification of CD30CLPD lesions.
In this regard, Bekkenk et al. (2000) reported their
experience with 110 Dutch patients with LyP and 79 with
pcALCL. In their study, 2 of 118 (1.7%) LyP patients and 4 of
79 (5.1%) with pcALCL died as a result of lymphoma
compared with 3 of 103 (2.9%) LyP patients and 2 of 13
(15.4%) pcALCL in our study. Death rates among LyP-A or -B,
LyP-C, and pcALCL in Bekkenk’s study were not significantly
different (P¼0.536, w2-test), whereas the difference was
significant in our study (P¼0.033). In addition, they did not
identify any clinical or histopathological finding that corre-
lated significantly with tumor progression by univariate
analysis, including age or CD30CLPD subtype. Although
the median ages for LyP and pcALCL at the time of study entry
for each patient population were nearly identical, the median
follow-up times were considerably longer for our patients
(118 months for LyP and 114 months for pcALCL for our
patients compared with 77 months for LyP and 61 months for
pcALCL for Bekkenk’s patients). Because disease progression
and the development of systemic involvement often requires
years to occur (Bekkenk et al., 2000; Gruber et al., 2006), this
could account for the difference in the observed death rates
for the two patient populations.
Our study showed that sCD30 and sCD25 are increased in
early MF and high sCD30 but not sCD25 levels correlated
with worse overall and disease-related survival in a Cox
model that included advanced age. The risk of death from
progressive disease in this MF cohort was quite low (B4%),
but similar to what other groups have reported (Kim et al.,
1996; van Doorn et al., 2000). Edinger reported that frequent
dermal CD30þ cells were an independent adverse prog-
nostic factor in nontransformed MF (Edinger et al., 2009).
Because we studied only CD30-low early MF cases, we could
not confirm the prognostic significance of CD30þ cell
numbers in skin lesions of the MF cohort. It is likely that
increased sCD30 levels in early MF cases are derived in part
from CD30-expressing non-neoplastic cells, and the observa-
tion that sCD30 values did not correlate with clinical
response suggests skin lesions are not the only source of
sCD30 in MF.
Our study showed a significantly positive correlation
between sCD30 levels and sCD25, IL-6, and IL-8, as well as
sCD40L, suggesting that CD30þ cells are secreting these
proteins, but not IL-4 nor other Th2 cytokines. In vitro studies
confirmed that sCD30, sCD25, IL-6, and to a lesser degree
IL-8, but not CD40L, were secreted by CD30CLPD-derived
cells. The absence of IL-4 and IL-5 in CD30CLPD-derived
supernatants and lack of concordance between sCD30 and
IL-4 or IL-5 levels in patient sera suggest that CD30þ
neoplastic cells do not closely resemble Th2 cells.
Despite the variable histology between individual lesions
of patients with CD30CLPD, we found significant correlation
between sCD30 levels and histopathological subtypes in our
patients, possibly due to selection of clinically advanced
lesions for biopsy. If sCD30 was secreted by neoplastic cells
in vivo, one might expect serum levels to reflect the total
number of CD30þ neoplastic cells in skin infiltrates, which
depend on (1) the number of lesions and (2) the average
density of CD30þ cells. Neither variable can reliably be
determined in clinical practice, suggesting the need for a
serological biomarker.
Our studies indicate that IL-6 is increased in CD30CLPD
cases and in Mac2A cells, which have a 20-fold amplification
of IL-6 gene expression compared with Mac1 cells from
earlier disease (Li et al., 2001). Several studies indicate that
CD30þ neoplastic cells from sALCL secrete IL-6, and that
IL-6 can function as an autocrine growth factor (Siebert et al.,
2007). Therefore, high serum IL-6 levels may portend a poor
prognosis, and, in our study, an above normal level of IL-6
identified CD30CLPD patients with a worse survival from
disease-related death but not overall death as the event.
However, the number of patients with progressive
CD30CLPD was small and further studies are required to
confirm this finding.
Our observation that IL-8 serum levels correlate signifi-
cantly with sCD30 levels in both CD30CLPD (rho¼0.322)
and early MF (rho¼0.435), and that 35% of CD30-
expressing tumor controls had elevated IL-8 values and
absolute values significantly higher than other groups,
suggests that IL-8 is secreted by CD30þ neoplastic cells.
Furthermore small amounts of IL-8 were secreted by
CD30CLPD-derived cells in vitro. A previous study by one
of the authors (MEK) revealed tumor cell secretion of IL-8 and
increased serum levels in cases of neutrophil-rich pcALCL
(Burg et al., 2003).
One hypothesis to explain the correlation between
increased sCD30 levels and adverse prognosis is that high
sCD30 (and sCD25) levels reflect a general state of immune
activation, perhaps to a persistent antigen, that predisposes
susceptible individuals to development and/or progression of
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CD30CLPD and MF (Burg et al., 2001; Chechlinska et al.,
2010; Vendrame and Martinez-Maza, 2011). A possible
mechanism is that cross-linking of cell-surface CD30 causes
upregulation of NF-kB (Levi et al., 2000), which activates
anti-apoptotic C-FLICE in cutaneous ALCL cells (Braun et al.,
2010). A similar mechanism may be operative in MF in which
NF-kB, a pro-survival transcription factor, is constitutively
expressed (Izban et al., 2000).
A prospective study is needed to confirm or refute our
hypothesis that patients with CD30CLPD and above normal
serum values for sCD30, sCD25, or IL-6 (and early MF
patients with high sCD30 levels) are at increased risk for
disease progression or development of an associated lym-
phoma. Accordingly, we suggest that sCD30, sCD25, and IL-
6 be measured as part of the baseline evaluation, and if any
biomarker is increased such patients should undergo staging
procedures (e.g., PET scan) and be more closely monitored by
clinical examinations than might otherwise be done. In this
context, it is important to exclude other possible explanations
for a rise in sCD30 or sCD25, such as autoimmune diseases
(Kadin, 2000). We also suggest that biomarker levels be
measured at regular intervals (6 to 12 months) to determine
whether an increased baseline value persists or a value
changes from normal to persistently high during follow-up.
This might prompt repeat staging procedures.
Our observations on a small number of patients (eight)
suggest that there was an inconstant correlation between
observed clinical responses and serum levels of sCD30 and
sCD25 before and after treatment. Nevertheless, persistent
elevation of sCD30, sCD25, or IL-6 in the face of a favorable
treatment response might identify patients at risk for poor
outcome. Conceivably, a high baseline sCD30 could even be
a harbinger of B-lymphoproliferative disorders known to be
associated with MF (Barzilai et al., 2006; Hallermann et al.,
2007; Herro et al., 2009; Purdue et al., 2009).
MATERIALS AND METHODS
Sera separated and frozen/stored in 1ml vials at 80 1C within
1 hour of phlebotomy during clinical evaluation of 103 patients with
LyP, 13 patients with pcALCL, and 16 patients with LyP or pcALCL
coexisting with patch or plaque phase MF were retrieved from the
cutaneous lymphoma tissue repository at Johns Hopkins University
and studied for cytokine expression at ARUP laboratories (Salt Lake
City, UT). This study was conducted in accordance with the
Declaration of Helsinki Principles and approved by the Institutional
Review Board at Johns Hopkins Medical Institute. Patient consent
was not required because studies were conducted on de-identified
residual sera. LyP cases were subclassified as types A, B, or C
(Willemze et al., 2005). Because concurrent frozen samples from
normal volunteers were not available, sera from 96 patients with
early MF (stage IA) and 22 patients with benign ISD, as well as
absent or rare CD30þ cells in the dermal infiltrate, were selected to
represent CD30-low controls. Sera from 19 patients with various
CD30-expressing cutaneous tumors (20–90% positivity by IHC) were
studied as a CD30-high control group. Detailed composition of
control groups is provided in the legend of Table 1.
Test reference intervals for 36 healthy individuals established at
ARUP laboratory were used to define an abnormally high result for
each cytokine or cytokine receptor, except sCD30, for which 151
healthy donors were used (Pavlov et al., 2009). Normal ranges
measured using the multi-analyte fluorescent detection method are
as follows: IL-1b (0–36pgml1), IL-2 (0–12 pgml1), IL-2R/sCD25
(0–1,033 pgml1), IL-12 (0–6 pgml1), and IL-4, IL-5, IL-6, IL-8,
IL-13, and IFN-g (0–5 pgml1). Normal ranges for other markers
measured by ARUP Luminex-based assays (ARUP Laboratory) were
sCD30 (1–29 ngml1), sCD40L (0–244 pgml1), and transforming
growth factor-b (3.5–13.9 ngml1). For correlation with sCD30
findings, sCD30L/CD153 was measured using ELISA (Bender
MedSystems, Burlingame, CA).
Three CD30þ ALCL lines (Mac-1, Mac-2A, JB-6) were examined
for secretion of cytokines/cytokine receptors in vitro. Cultures were
seeded with 106 viable tumor cells and incubated in tissue culture
media. At 24 and 48hours, aliquots of conditioned medium were
collected, frozen, and sent to ARUP laboratory for analysis. Mac-1
and Mac-2A are ALK-negative lines were derived from early and
advanced disease, respectively, of a patient with progressive
CD30CLPD. JB6 is an ALKþ cell line derived from sALCL.
Statistics
Because most continuous variables did not have a normal
distribution, nonparametric Kruskal–Wallis analysis of variance on
ranks test was used to test differences of median values among
independent groups. Fisher’s and Pearson’s w2 exact tests tested
categorical data in 2 2 and 2 3 tables, respectively. The strength
of association between pairs of cytokines/cytokine receptors was
analyzed using Spearman’s rank correlation coefficient. Wilcoxon
signed rank exact test was used for differences in median values in
pre- and post-treatment samples. Prognostic significance of mea-
sured values was tested in the Cox proportional hazards model, and
differences in survival were determined using the Kaplan–Meier
method and Log-rank test of Mantel. Survival was determined from
time of blood sampling (usually at presentation) to last contact.
Both disease-related and all causes of death were used as non-
censored events. The Holm–Sidak Test was used for pairwise compa-
risons among multiple survival curves. Statistical packages used for
data analysis were SYSTAT10 and SPSS 13.0 for Windows, SPSS
(Chicago, IL); StatXact 3 and EGRET for Windows, Cytel (Cambridge,
MA); and SigmaStat3, Systat Software (Point Richman, CA).
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